Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 18/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 18/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30382126 | 1.00 | HCRTR1 (0.42) | HCRTR1HCRTR2CCR1ADORA2A | |
| SCHEMBL22251076 | 0.86 | HCRTR1 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL2440105 | 0.86 | CCR1 (0.40) | HCRTR1HCRTR2CCR1 | |
| SCHEMBL29994822 | 0.85 | HCRTR1 (0.40) | HCRTR1HCRTR2ADORA2A | |
| SCHEMBL13104652 | 0.84 | HCRTR1 (0.45) | HCRTR1HCRTR2 | |
| SCHEMBL24914919 | 0.83 | CCR1 (0.35) | HCRTR1HCRTR2CCR1 | |
| SCHEMBL7803702 | 0.82 | CCR1 (0.38) | HCRTR1HCRTR2CCR1 | |
| SCHEMBL130926 | 0.82 | HCRTR1 (0.41) | HCRTR1HCRTR2ADORA2A | |
| SCHEMBL20910195 | 0.82 | HCRTR1 (0.41) | HCRTR1HCRTR2ADORA2A | |
| SCHEMBL536812 | 0.82 | HCRTR1 (0.41) | HCRTR1HCRTR2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195447-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ARCUS BIOSCIENCES, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240376081-A1 | POLYMORPH AND APPLICATION OF PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-11-14 | — | — | US | disclosed |
| CN-116981669-B | Pyrimidine or pyrido heterocyclic adenosine receptor inhibitor, preparation method and application thereof | 上海齐鲁制药研究中心有限公司 | 2024-08-30 | — | — | CN | disclosed |
| EP-4403553-A1 | POLYMORPH AND APPLICATION OF PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) | 2024-07-24 | — | — | EP | disclosed |
| CN-118373808-A | Substituted pyrimidine or pyridine amine derivatives, compositions thereof and pharmaceutical use thereof | 上海海雁医药科技有限公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-113015523-B | Solid forms of azopyrimidine compounds | 艾库斯生物科学有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-11993584-B2 | Solid forms of an azolopyrimidine compound | ARCUS BIOSCIENCES, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| CN-113748110-B | Substituted pyrimidine or pyridine amine derivatives, compositions thereof and pharmaceutical use thereof | 上海海雁医药科技有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117794913-A | Polymorphs of pyrimidine derivatives and pharmaceutically acceptable salts thereof and uses thereof | 上海海雁医药科技有限公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4310082-A2 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | Arcus Biosciences, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-102076692-B | Triazolo [4,5-D ] pyrimidine derivatives and their use as purine receptor antagonists | VERNALIS RESEARCH LTD. (GB) | 2014-10-22 | — | — | CN | disclosed |
| US-20130245044-A1 | TRIAZOLO[4, 5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2013-09-19 | — | — | US | disclosed |
| US-8450328-B2 | Triazolo[4,5-D]pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2013-05-28 | — | — | US | disclosed |
| EP-2321321-B1 | TRIAZOLO [4, 5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS R&D LTD (GB) | 2012-02-08 | — | — | EP | disclosed |
| US-20110172252-A1 | TRIAZOLO[4,5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED | 2011-07-14 | — | — | US | disclosed |
| CN-102076692-A | Triazolo [4,5-D ] pyrimidine derivatives and their use as purine receptor antagonists | VERNALIS R&D LTD | 2011-05-25 | — | — | CN | disclosed |
| EP-2321321-A1 | TRIAZOLO [4, 5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | Vernalis (R&D) Limited (GB) | 2011-05-18 | — | — | EP | disclosed |
| WO-2009156737-A1 | TRIAZOLO [4, 5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2009-12-30 | — | — | WO | disclosed |
| US-5280096-A | Optically active polymer | UNIVERSITY OF NEW MEXICO (US) | 1994-01-18 | — | — | US | disclosed |
| US-5166062-A | Reaction a mixture of acyl esters with enzymes and selectively deacylating followed by separation | UNIVERSITY OF NEW MEXICO (US) | 1992-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172252-A1 | TRIAZOLO[4,5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | HCRTR1 816/4885HCRTR2 1055/4885CCR1 1357/4885 |
| US-11993584-B2 | Solid forms of an azolopyrimidine compound | DPYD, CDK4, TPMT | HCRTR1 4598/4885HCRTR2 4327/4885CCR1 2587/4885 |
| US-12195447-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ADORA2A, ADORA2B, ADORA1 | HCRTR1 1835/4885HCRTR2 1345/4885CCR1 447/4885 |
| US-20130245044-A1 | TRIAZOLO[4, 5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | HCRTR1 816/4885HCRTR2 1055/4885CCR1 1357/4885 |
| US-20240376081-A1 | POLYMORPH AND APPLICATION OF PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ADORA2B, ADORA2A, ADORA3 | HCRTR1 1827/4885HCRTR2 1265/4885CCR1 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.